Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Listen to this summary
This study investigates the role of galectin-1 (Gal-1) in driving monocyte hyperinflammation in myeloproliferative neoplasms (MPNs). The authors demonstrate that elevated Gal-1 levels in MPN monocytes enhance inflammatory cytokine production through TLR4 and NF-κB signaling pathways, suggesting that targeting Gal-1 could represent a novel therapeutic strategy for managing MPN-related inflammation.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Blood
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Blood
Direct and indirect regulation of fetal globin transcript by RNA-binding protein IGF2BP1
Jun 22, 2026 · Blood
Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration
Jun 20, 2026 · Blood
Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD
More in Internal Medicine
View all →Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 24, 2026 · Journal of hepatology
Regression of liver cirrhosis
Jun 24, 2026 · Journal of addiction medicine
Medicaid Prior Authorization and Discontinuation of Buprenorphine
Jun 24, 2026 · Journal of addiction medicine
Implementation of Dyadic Care to Support Clinical, Administrative, and Service Wraparound Needs for the Opioid-Exposed Mother and Infant
Jun 24, 2026 · Critical care medicine
Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
